Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shot up 0.9% on Tuesday . The stock traded as high as $49.58 and last traded at $49.12. 1,275,759 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 2,790,150 shares. The stock had previously closed at $49.55.

Several equities analysts have recently issued reports on the stock. ValuEngine lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Monday. Royal Bank Of Canada restated a “buy” rating and issued a $64.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday. Barclays PLC initiated coverage on Sarepta Therapeutics in a research note on Wednesday, September 6th. They set an “equal weight” rating and a $46.00 price objective on the stock. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. Finally, Credit Suisse Group lifted their target price on Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an “outperform” rating in a report on Thursday, September 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fifteen have assigned a buy rating to the company. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus target price of $62.79.

The firm has a 50-day moving average of $42.14 and a 200-day moving average of $35.85. The company’s market cap is $3.15 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. During the same quarter in the prior year, the company earned ($1.19) EPS. The company’s revenue was up 350000.0% on a year-over-year basis. On average, equities research analysts forecast that Sarepta Therapeutics, Inc. will post ($1.22) earnings per share for the current fiscal year.

In other news, SVP Alexander Cumbo sold 5,918 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the transaction, the senior vice president now owns 22,793 shares in the company, valued at $934,513. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Shamim Ruff sold 12,138 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $42.97, for a total value of $521,569.86. Following the completion of the transaction, the senior vice president now owns 27,312 shares in the company, valued at approximately $1,173,596.64. The disclosure for this sale can be found here. Insiders have sold a total of 78,056 shares of company stock valued at $3,224,208 over the last three months. Corporate insiders own 9.60% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Prentiss Smith & Co. Inc. grew its holdings in Sarepta Therapeutics by 772.2% during the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after buying an additional 3,166 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new stake in Sarepta Therapeutics in the 1st quarter valued at $127,000. PNC Financial Services Group Inc. raised its position in Sarepta Therapeutics by 150.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,800 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares during the last quarter. Finally, Edge Wealth Management LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter valued at $175,000. 65.41% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Trading Up -0.9%” was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/sarepta-therapeutics-inc-srpt-trading-up-0-9/1605934.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.